ANL 31.35 Decreased By ▼ -0.20 (-0.63%)
ASC 20.90 Increased By ▲ 0.10 (0.48%)
ASL 23.90 Decreased By ▼ -0.10 (-0.42%)
BOP 8.41 Increased By ▲ 0.24 (2.94%)
BYCO 10.04 Decreased By ▼ -0.20 (-1.95%)
FCCL 22.20 Decreased By ▼ -0.40 (-1.77%)
FFBL 27.44 Increased By ▲ 0.24 (0.88%)
FFL 20.79 Decreased By ▼ -0.41 (-1.93%)
FNEL 8.85 Decreased By ▼ -0.33 (-3.59%)
GGGL 27.45 Decreased By ▼ -0.58 (-2.07%)
GGL 47.10 Increased By ▲ 0.35 (0.75%)
HUMNL 7.40 Decreased By ▼ -0.15 (-1.99%)
JSCL 22.50 Decreased By ▼ -0.43 (-1.88%)
KAPCO 39.80 Decreased By ▼ -0.30 (-0.75%)
KEL 3.92 Decreased By ▼ -0.02 (-0.51%)
MDTL 3.73 Decreased By ▼ -0.08 (-2.1%)
MLCF 44.27 Decreased By ▼ -0.83 (-1.84%)
NETSOL 165.95 Decreased By ▼ -1.40 (-0.84%)
PACE 7.67 Decreased By ▼ -0.36 (-4.48%)
PAEL 34.01 Decreased By ▼ -0.86 (-2.47%)
PIBTL 11.25 Decreased By ▼ -0.10 (-0.88%)
POWER 9.20 Decreased By ▼ -0.15 (-1.6%)
PRL 23.80 Decreased By ▼ -0.33 (-1.37%)
PTC 11.73 Decreased By ▼ -0.02 (-0.17%)
SILK 1.82 Decreased By ▼ -0.01 (-0.55%)
SNGP 49.60 Decreased By ▼ -1.58 (-3.09%)
TELE 15.06 Decreased By ▼ -0.51 (-3.28%)
TRG 166.20 Decreased By ▼ -1.86 (-1.11%)
UNITY 42.97 Decreased By ▼ -0.87 (-1.98%)
WTL 3.74 Decreased By ▼ -0.08 (-2.09%)
BR100 5,167 Decreased By ▼ -9.46 (-0.18%)
BR30 26,489 Decreased By ▼ -221.93 (-0.83%)
KSE100 47,687 Increased By ▲ 14.31 (0.03%)
KSE30 19,130 Increased By ▲ 22.74 (0.12%)

Coronavirus
VERY HIGH Source: covid.gov.pk
Pakistan Deaths
23,087
3924hr
Pakistan Cases
1,011,708
3,26224hr
6.6% positivity
Sindh
369,245
Punjab
353,695
Balochistan
29,681
Islamabad
85,947
KPK
142,139
Business & Finance

J&J raises forecasts, estimates $2.5bn in COVID-19 vaccine sales

  • Pfizer and Moderna forecast $26 billion and $19.2 billion in annual sales of their vaccines, respectively
  • J&J raised its expectations for full-year sales to a range of $93.8 billion to $94.6 billion including contribution from the single-dose vaccine, and to $91.3 billion-$92.1 billion for the rest of the business
21 Jul 2021

Johnson & Johnson on Wednesday raised its overall revenue estimate for the year and forecast $2.5 billion in sales of its COVID-19 vaccine, which has fallen way behind rival shots from Pfizer and Moderna as the company deals with vaccine production issues and safety concerns.

Although Johnson & Johnson's shot was approved in the United States months after vaccines from Pfizer Inc and Moderna Inc, its vaccine outlook pales in comparison with its peers and reflects the widening gap in the vaccine race.

Pfizer and Moderna forecast $26 billion and $19.2 billion in annual sales of their vaccines, respectively.

The J&J shot, once touted as an important tool for vaccinations in hard-to-reach areas, has already delayed deliveries in the United States and Europe. It has also been linked to a very rare, potentially life-threatening blood-clotting condition.

J&J's says its Covid-19 vaccine effectively combats Delta variant

J&J raised its expectations for full-year sales to a range of $93.8 billion to $94.6 billion including contribution from the single-dose vaccine, and to $91.3 billion-$92.1 billion for the rest of the business.

It had previously forecast sales to come in between $90.6 billion and $91.6 billion.

The outlook was driven by recovery in sales at its medical devices unit and higher demand for treatments such as psoriasis and Crohn's disease drug Stelara.

The company had recorded $164 million in vaccine sales in for the second quarter.

Pfizer Inc and Moderna Inc have forecast $26 billion and $19.2 billion in annual sales of their vaccines, respectively. Both shots were approved in the United States last year, while J&J's vaccine was approved this year.

Both companies expect to profit from their vaccines, while Johnson & Johnson has said it will make the vaccine available on a not-for-profit basis during the pandemic.

Moderna, J&J to make up bulk of Germany's 2022 extra vaccine purchases

In the second quarter, J&J earned $2.48 per share, beating analysts' average estimate of $2.27 per share, according to IBES data from Refinitiv.

The company reported $23.31 billion in total sales, above the estimate of $22.21 billion.

Shares of the company rose 1% before the opening bell.